Version 1
: Received: 29 June 2024 / Approved: 1 July 2024 / Online: 1 July 2024 (08:12:17 CEST)
How to cite:
Correia, A. F.; Oliveira, C. G. C.; Jr., D. C. O.; Pereira, M. C.; Carvalho, F. A.; Martins, E. D. C.; Oliveira, D. C. Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Preprints2024, 2024070019. https://doi.org/10.20944/preprints202407.0019.v1
Correia, A. F.; Oliveira, C. G. C.; Jr., D. C. O.; Pereira, M. C.; Carvalho, F. A.; Martins, E. D. C.; Oliveira, D. C. Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Preprints 2024, 2024070019. https://doi.org/10.20944/preprints202407.0019.v1
Correia, A. F.; Oliveira, C. G. C.; Jr., D. C. O.; Pereira, M. C.; Carvalho, F. A.; Martins, E. D. C.; Oliveira, D. C. Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Preprints2024, 2024070019. https://doi.org/10.20944/preprints202407.0019.v1
APA Style
Correia, A. F., Oliveira, C. G. C., Jr., D. C. O., Pereira, M. C., Carvalho, F. A., Martins, E. D. C., & Oliveira, D. C. (2024). Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Preprints. https://doi.org/10.20944/preprints202407.0019.v1
Chicago/Turabian Style
Correia, A. F., Estêvão de Campos Martins and Dinaldo C. Oliveira. 2024 "Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention" Preprints. https://doi.org/10.20944/preprints202407.0019.v1
Abstract
Abstract: Acute coronary syndrome (ACS) represents the most severe manifestation of coronary artery disease (CAD), characterized by a particularly poor prognosis. Consequently, primary percutaneous coronary intervention (PPCI) is imperative in the event of acute ST-elevation myocardial infarction (STEMI). Interleukin-22 (IL-22) may be a new CAD biomarker because it signals and regulates immune and inflammatory responses. Objectives: To investigate the differences in circulating IL-22 levels between patients with STEMI undergoing PPCI and healthy controls; and to determine if these differences are associated with the culprit coronary artery, door-to-balloon time (DBT), final angiographic result, CAD classification, and the presence of diabetes mellitus (DM). Methods: A total of 280 participants were recruited, comprising 210 STEMI cases and 70 healthy controls. Participants underwent clinical and angiographic evaluation, and serum IL-22 levels were measured using enzyme-linked immunosorbent assay (ELISA). Data analysis was performed using the Mann-Whitney and Fisher’s tests, with a p < 0.05 significant. Results: Serum IL-22 levels were lower in cases (149.63, 84.99–294.56) than in controls (482.67, 344.33–641.00), p < 0.001. Lower IL-22 levels were associated with the right coronary artery (RCA) (144.57, 70.84–242.43; 146.00, 63.60–279.67; 191.71, 121.80–388.97), p = 0.033. IL-22 was lower with shorter DBT (≤ 60 minutes, 106.00, 49.60–171.71; > 60 minutes, 153.00, 88.86–313.60), p = 0.043. Conclusions: IL-22 levels were significantly lower in patients with STEMI compared to healthy controls.
Keywords
IL-22; STEMI; ACS; Atherosclerosis
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
